LOS ANGELES, Jan. 08, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer and Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 4:30 p.m. PST.
A live webcast of RadNet's presentation can be accessed here and is available for replay viewing. The 42nd Annual J.P. Morgan Healthcare Conference will take place at the Westin St. Francis Hotel, San Francisco.
Details for RadNet's Presentation: | ||
Date: | Wednesday, January 10th, 2024 | |
Time: | 4:30 p.m. PST | |
Location: | The Westin St. Francis Hotel, San Francisco, CA |
About RadNet, Inc.
RadNet, Inc., is the leading national provider of free-standing, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 366 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware, New Jersey, New York, Florida, and Arizona. Together with affiliated radiologists, including full-time and per diem employees and technologists, RadNet has over 9,000 employees.
For more information, visit http://www.radnet.com.
Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2800
Last Trade: | US$72.25 |
Daily Change: | -0.18 -0.25 |
Daily Volume: | 405,798 |
Market Cap: | US$5.350B |
January 08, 2025 December 04, 2024 December 02, 2024 December 02, 2024 December 01, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load